JP2019055982A5 - - Google Patents

Download PDF

Info

Publication number
JP2019055982A5
JP2019055982A5 JP2018228685A JP2018228685A JP2019055982A5 JP 2019055982 A5 JP2019055982 A5 JP 2019055982A5 JP 2018228685 A JP2018228685 A JP 2018228685A JP 2018228685 A JP2018228685 A JP 2018228685A JP 2019055982 A5 JP2019055982 A5 JP 2019055982A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
compound
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018228685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019055982A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019055982A publication Critical patent/JP2019055982A/ja
Publication of JP2019055982A5 publication Critical patent/JP2019055982A5/ja
Pending legal-status Critical Current

Links

JP2018228685A 2012-06-07 2018-12-06 Pin1の阻害のための方法および組成物 Pending JP2019055982A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656806P 2012-06-07 2012-06-07
US61/656,806 2012-06-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015516246A Division JP6449764B2 (ja) 2012-06-07 2013-06-07 Pin1の阻害のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2019055982A JP2019055982A (ja) 2019-04-11
JP2019055982A5 true JP2019055982A5 (cg-RX-API-DMAC7.html) 2019-06-27

Family

ID=49712688

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015516246A Expired - Fee Related JP6449764B2 (ja) 2012-06-07 2013-06-07 Pin1の阻害のための方法および組成物
JP2018228685A Pending JP2019055982A (ja) 2012-06-07 2018-12-06 Pin1の阻害のための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015516246A Expired - Fee Related JP6449764B2 (ja) 2012-06-07 2013-06-07 Pin1の阻害のための方法および組成物

Country Status (6)

Country Link
US (3) US9730941B2 (cg-RX-API-DMAC7.html)
EP (1) EP2858648B1 (cg-RX-API-DMAC7.html)
JP (2) JP6449764B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013271378A1 (cg-RX-API-DMAC7.html)
CA (1) CA2875798A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013185055A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
WO2015143190A1 (en) * 2014-03-21 2015-09-24 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1
TWI745271B (zh) * 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
WO2016011268A1 (en) * 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
JP7205830B2 (ja) * 2017-08-07 2023-01-17 国立大学法人広島大学 新規アントラニル酸系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤
KR102349523B1 (ko) * 2020-02-03 2022-01-07 경기대학교 산학협력단 신규한 광학 활성 비스인도릴메탄설파메이트 유도체 및 이를 포함하는 신경병증 치료용 조성물
CN116096367A (zh) * 2020-06-08 2023-05-09 苏黎世大学 Frs2–fgfr相互作用的小分子抑制剂及其在医学、在预防和治疗癌症中的用途
JP7835423B2 (ja) * 2020-11-17 2026-03-25 アメニス バイオサイエンス インク Covid-19の治療剤又は予防剤
CN116236492A (zh) * 2023-02-01 2023-06-09 北京中医药大学 番泻苷a用于制备改善阿尔茨海默症的产品的用途
WO2025024685A2 (en) * 2023-07-27 2025-01-30 Thomas Jefferson University Inhibitors of cib1 interactions and methods of use
JPWO2025053222A1 (cg-RX-API-DMAC7.html) * 2023-09-08 2025-03-13
CN120939019B (zh) * 2025-08-14 2026-06-26 电子科技大学 嘧啶并三嗪二酮衍生物在制备抑制人类蛋白酶caspase-1活性的药物中的应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
JP3537141B2 (ja) 1992-10-30 2004-06-14 ザ ゼネラル ホスピタル コーポレーション 新種蛋白質分離のための相互作用を用いる補捉システム
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US7125677B2 (en) 1995-11-13 2006-10-24 The Salk Institute For Biological Studies NIMA interacting proteins
US5972697A (en) 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6462173B1 (en) 1997-09-08 2002-10-08 Max-Planck-Gesellschaft Zur Forderung Der Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases
KR100274842B1 (ko) 1998-10-01 2001-03-02 김효근 미립구를 이용한 레티노익산의 서방형 약물방출 시스템
US6495376B1 (en) 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
US7141234B1 (en) 1999-09-21 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Imaging of drug accumulation as a guide to antitumor therapy
US20020025521A1 (en) 1999-11-29 2002-02-28 Lu Kun Ping Pin1 as a marker for abnormal cell growth
KR20020084273A (ko) 2000-03-31 2002-11-04 화이자 프로덕츠 인코포레이티드 신규한 피페라진 유도체
CA2414379A1 (en) 2000-06-30 2002-01-10 Troy Schultz Method and apparatus for a gis based search engine utilizing real time advertising
US20020106348A1 (en) 2000-07-12 2002-08-08 Peng Huang Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
EP1446044A4 (en) 2001-02-09 2007-08-08 Pintex Pharmaceuticals Inc PIN1 AS A MARKER FOR PROSTATE CANCER
WO2002065091A2 (en) 2001-02-09 2002-08-22 Pintex Pharmaceuticals, Inc. Pin1 as marker for abnormal cell growth
AU2002303712A1 (en) 2001-05-11 2002-11-25 Beth Israel Deaconess Medical Center Novel telomerase inhibitors and uses therefor
US20050159485A1 (en) 2002-01-04 2005-07-21 Jost-Price Edward R. Combinations for the treatment of immunoinflammatory disorders and proliferative skin diseases
EP1476120B1 (en) 2002-02-21 2010-09-29 Duke University Treatment methods using anti-cd22 antibodies
US20040180889A1 (en) 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
AU2003213698A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Methods for designing specific inhibitors for pin1 proline isomerase and pin1-related molecules
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US7161060B1 (en) 2002-07-16 2007-01-09 Albert Einstein College Of Medicine Of Yeshiva University Transgenic mice comprising a genomic human tau transgene
WO2004016751A2 (en) 2002-08-15 2004-02-26 Beth Israel Deaconess Medical Center Methods of treating neurodegenerative diseases
US20050147608A1 (en) 2003-05-08 2005-07-07 Beth Israel Deaconess Medical Center, Inc. Novel regulatory mechanisms of NF-kappaB
WO2005027727A2 (en) 2003-09-19 2005-03-31 Beth Israel Deaconess Medical Center Use of pin1 inhibitors for treatment of cancer
US20050250742A1 (en) 2004-03-03 2005-11-10 Pfizer Inc. Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting NIMA (PIN1)
AU2005257997B2 (en) 2004-06-18 2012-04-05 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
EP1771556A2 (en) 2004-07-15 2007-04-11 Vernalis PLC Determination of a phosphorylation site in ppiase domain of pin1 and uses therefor
EP1776130A2 (en) 2004-07-15 2007-04-25 Vernalis PLC Pin1-modulating compounds and methods of use thereof
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
CA2605508A1 (en) 2005-05-12 2006-11-23 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US20090124023A1 (en) 2006-05-12 2009-05-14 Ailan Guo Reagens for the Detection of Protein Acetylation Signaling Pathways
US7728110B2 (en) 2006-05-19 2010-06-01 Amgen, Inc. Antibodies to SARS coronavirus
CN107652212B (zh) 2007-01-15 2019-11-15 于崇曦 维生素a酸类和类维生素a酸化合物的前药
WO2008137488A1 (en) 2007-05-01 2008-11-13 Purdue Research Foundation Methods for controlling inflammatory and immunological diseases
JP5149388B2 (ja) 2007-09-12 2013-02-20 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 黄斑変性症を処置するための組成物及び方法
MX2010004251A (es) 2007-10-16 2010-08-30 Sbi Biotech Co Ltd Anticuerpo anti-bst2.
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
US20110206691A1 (en) 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
TW201006474A (en) 2008-04-18 2010-02-16 Reata Pharmaceuticals Inc Natural products including an anti-flammatory pharmacore and methods of use
CN101591280B (zh) 2008-05-30 2012-08-22 安徽医科大学 具有肿瘤诱导分化作用的类维甲酸衍生物及其药物组合物与用途
WO2010081488A1 (en) 2009-01-15 2010-07-22 Humanitas Mirasole S.P.A. Nitric oxide furoxan derivative compounds endowed with antitumoral activity
WO2010141738A2 (en) 2009-06-03 2010-12-09 President And Fellows Of Harvard College Compositions and method for inhibiting tumor growth
US8377639B2 (en) 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
WO2010151799A2 (en) * 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
JP2013501919A (ja) 2009-08-07 2013-01-17 アフィニマーク テクノロジーズ,インコーポレイテッド 脳脊髄液の免疫的識別のための装置および方法
LT2483416T (lt) 2009-10-02 2017-04-25 The Regents Of The University Of California Monokloniniai antikūnai
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
IT1398522B1 (it) 2010-02-23 2013-03-01 Istituto Oncologico Veneto Irccs Nuovi derivati furossanici idrosolubili aventi attivita' antitumorale.
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
ES2835716T3 (es) 2013-03-15 2021-06-23 Beth Israel Deaconess Medical Ct Inc Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación
WO2015143190A1 (en) 2014-03-21 2015-09-24 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions

Similar Documents

Publication Publication Date Title
JP2015518902A5 (cg-RX-API-DMAC7.html)
Müller et al. Recommended tool compounds and drugs for blocking P2X and P2Y receptors
AU2021286266B2 (en) Polymorphs of selinexor
TWI377200B (en) Compounds, compositions and methods of using same for modulating uric acid levels
JP2009523730A5 (cg-RX-API-DMAC7.html)
Müller et al. Agonists and antagonists for purinergic receptors
JP5099794B2 (ja) 新規化合物、組成物、及び使用方法
AU2023202694A1 (en) Compounds and methods for treating neurological and cardiovascular conditions
US20190085008A1 (en) Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
WO2023215991A1 (en) Dna-pk inhibitor compounds and uses thereof
CA3072205A1 (en) Methods and compositions for modulating splicing
JP2016527315A5 (cg-RX-API-DMAC7.html)
DK2827860T3 (en) USE OF A pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
NO309025B1 (no) Anvendelse av substituerte adeninderivater for fremstilling av preparater til behandling av multippel sklerose
AU2014203484A1 (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors
US9415046B2 (en) Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
CN106714793B (zh) 琥珀酸脱氢酶抑制剂(SDHi’s)
JP2010526105A5 (cg-RX-API-DMAC7.html)
Erlinge P2Y receptors in health and disease
EP3019874A2 (en) Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14
Khandazhinskaya et al. Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects
TWI233359B (en) Pharmaceutical composition for treating neoplasm
US20220193106A1 (en) Nucleobase analogue derivatives and their applications
da Silva Ferreira et al. Potential therapeutic applications of P2 receptor antagonists: from bench to clinical trials
JP2002515892A (ja) サイトカインが関係する疾患治療法